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Abstract  
 
Antony J Workman, Kathleen A Kane, Andrew C Rankin. The contribution of ionic currents to 
changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. 
Objective: To investigate changes in human atrial single cell functional electrophysiological properties 
associated with chronic atrial fibrillation (AF), and the contribution to these of accompanying ion 
current changes. Methods: The whole cell patch clamp technique was used to record action potentials, 
the effective refractory period (ERP) and ion currents, in the absence and presence of drugs, in 
enzymatically isolated myocytes from 11 patients with chronic (>6 months) AF and 39 patients in sinus 
rhythm. Results: Stimulation at high rates (up to 600 beats/min) markedly shortened late repolarisation 
and the ERP in cells from patients in sinus rhythm, and depolarised the maximum diastolic potential 
(MDP). Chronic AF was associated with a reduction in the ERP at physiological rate (from 203±16 to 
104±15 ms, P<0.05), and marked attenuation in rate effects on the ERP and repolarisation. The 
abbreviated terminal phase of repolarisation prevented fast rate-induced depolarisation of the MDP in 
cells from patients with AF. The density of L-type Ca
2+
 (ICaL) and transient outward K
+
 (ITO) currents 
was significantly reduced in cells from patients with AF (by 60-65%), whilst the inward rectifier K
+
 
current (IK1) was increased, and the sustained outward current (IKSUS) was unaltered. Superfusion of 
cells from patients in sinus rhythm with nifedipine (10 micromol/L) moderately shortened 
repolarisation, but had no effect on the ERP (228±12 vs 225±11 ms). 4-aminopyridine (2 mmol/L) 
markedly prolonged repolarisation and the ERP (by 35%, P<0.05). However, the combination of these 
drugs had no effect on late repolarisation or refractoriness. Conclusion: Chronic AF in humans is 
associated with attenuation in adaptation of the atrial single cell ERP and MDP to fast rates, which may 
not be explained fully by accompanying changes in ICaL and ITO. 
 
Keywords: 
Discipline: experimental; Object of study: heart; Level of study: cellular; Field of study: 
electrophysiology, pathophysiology, pharmacology. Additional keywords: Supraventricular arrhythmia; 
arrhythmia (mechanisms); remodelling; myocytes; ion channels.
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Introduction 
 
 Chronic atrial fibrillation (AF) causes electrophysiological changes in the atria which promotes the 
perpetuation of the arrhythmia [1-5], a process known as AF-induced atrial electrophysiological 
remodelling. AF in humans involves multiple intra-atrial reentrant circuits [6], the maintenance of 
which depends upon a shortened atrial effective refractory period (ERP), slowed conduction, or both. 
An increased vulnerability to develop atrial tachyarrhythmias was correlated, in patients, with a lack of 
adaptation of the atrial ERP to increasing rate [7]. More recently, studies on goats [1] and dogs [2] have 
demonstrated the importance of a shortened atrial ERP, and its impaired rate adaptation, to the 
perpetuation of artificially-induced AF. Similar abnormalities in refractoriness have since been 
measured in patients immediately after cardioversion of AF, contributing to the growing body of 
evidence that reversible remodelling also occurs as a result of chronic AF in humans [8-10]. 
 The ERP is largely determined by the duration of final repolarisation, which depends upon the 
density, voltage-dependency and kinetics of a variety of sarcolemmal ion currents. Chronic pacing-
induced atrial remodelling in dogs involves a progressive attenuation in ERP rate adaptation which is 
paralleled by a reduction in L-type Ca
2+
 (ICaL) and transient outward K
+
 (ITO) currents, but no alteration 
in inward rectifier (IK1) or various delayed rectifier K
+
 (IK) currents [2]. In humans, atrial ICaL [11,12] 
and ITO [12,13] are also reduced in AF, due to ion channel transcriptional down-regulation [14,15]. 
However, the pattern of clinical AF-induced ionic remodelling is far from clear, since available data on 
currents other than ICaL and ITO are conflicting [12,15] and often inconsistent with the canine study [2]. 
 Moreover, the contribution of ionic remodelling to the alteration in functional electrophysiological 
properties such as the ERP and its rate adaptation, is also unclear. Indeed, the ERP has not been 
measured before in single atrial cells isolated from humans, with sinus rhythm (SR) or otherwise, and 
the pharmacological modulation of this important parameter has not yet been attempted in such cells. 
 During AF, the atria generally activate at rates >400 beats per min (bpm), and may reach 600 bpm 
[16]. Attenuation of action potential duration (APD) rate adaptation associated with human AF occurs 
at up to 240 bpm [12], but higher rates have not yet been studied. Fast atrial rate has been proposed as a 
potential trigger of electrophysiological remodelling by extending the depolarised time (and hence ICaL 
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activity) per cardiac cycle [4]. However, data on effects of fast rates on the human atrial cell membrane 
potential, or any alteration by AF, are currently lacking. 
 We aimed to investigate, in human atrial isolated myocytes, changes in functional 
electrophysiological properties associated with chronic AF (including rate adaptation of the ERP and 
membrane potential) and, with pharmacological modulation, the contribution to these changes of 
observed alterations in ion currents. 
 
 
Methods 
 
Cardiac myocyte isolation 
The tip of the right atrial appendage was obtained from 50 patients undergoing cardiac surgery, whose 
characteristics are shown in Table 1. Procedures approved by the institutional research ethics committee 
were followed, and each patient's informed consent was obtained. The investigation conforms with the 
principles outlined in the Declaration of Helsinki [17]. The tissue was transported to the laboratory for 
processing within 5 min of excision. Atrial cells were isolated by enzymatic dissociation and 
mechanical disaggregation, using a modification of the chunk method, described in detail previously by 
Harding et al [18] and Escande et al [19]. Briefly, excised tissue (weight: 0.25±0.02 g) was sliced into 
chunks and shaken (130 strokes/min) at 37 
o
C, under O2, in a nominally Ca
2+
-free solution, containing 
(mM) NaCl (120.0), KCl (5.4), MgSO4 (5.0), pyruvate (5.0), glucose (20.0), taurine (20.0), HEPES 
(10.0), nitrilotriacetic acid (5.0); pH 7.0. The chunks were incubated in this way for 12 min, with 
transfer to fresh Ca
2+
-free solution every 3 min. Protease (Type XXIV, Sigma, 4 U/ml) and CaCl2 (50 
µM) were added, and tissues were shaken for a further 45 min. The protease was then substituted by 
collagenase (Type 1, Worthington, 400 U/ml), and partially digested tissues were incubated for 
consecutive periods of 15, 15 and 20 min. The cell suspension obtained after each incubation was 
filtered through nylon gauze (200 µm mesh, Barr & Wray, Lanark, UK) and centrifuged at 40 g for 2 
min. The supernatant was removed and cells centrifuged again after their resuspension in 1 ml of a high 
[K
+
], low [Ca
2+
] solution ("KB" [20]), to wash off residual enzymes. Finally, the KB was replaced with 
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a 0.2 mM CaCl2-containing physiological salt solution for the independent storage in petri-dishes of the 
3 cell fractions, for up to 8 hours. 
 
Electrical recording technique 
Action potentials and ion currents were recorded using the whole cell patch clamp technique, with an 
Axopatch-1D amplifier (Axon Instruments). Cells were superfused (37 
o
C) at 1.5 ml/min (RC-24E fast 
exchange perfusion chamber, Warner) with a physiological salt solution containing (mmol/L): NaCl 
(130.0), KCl (4.0), CaCl2 (2.0), MgCl2 (1.0), glucose (10.0), HEPES (10.0), pH 7.4, with added 
nifedipine (10 µmol/L) and/or 4-aminopyridine, 4-AP (2 mmol/L) when required. Microelectrodes were 
constructed from thin walled, filamented borosilicate glass (Clark Electromedical) using a micropipette 
puller (Narishige PP-83), and heat polished to resistances of 5-10 MΩ. Electrodes were filled with an 
aspartate-based solution which contained (mM): L-aspartic acid (110.0), KCl (20.0), MgCl2 (1.0), 
EGTA (0.15), Na2ATP (4.0), Na2GTP (0.4), HEPES (5.0), pH 7.3. Using this solution, a liquid junction 
potential of +7±0.3 mV (n=6) was measured (bath relative to pipette) and was compensated for prior to 
seal formation [21]. Only single, isolated myocytes were selected for electrical recording, and both the 
cells' series resistance and capacity (4.5±0.3 MΩ and 77±3 pF, respectively; n=97 cells) were routinely 
compensated electronically prior to recording. The software program WinWCP (J Dempster, 
Strathclyde University) was used both to stimulate and record electrical activity. Current and voltage 
signals were low pass filtered at 5 kHz and digitised (Digidata 1200 A-D converter, Axon Instruments) 
prior to storage on magnetic and compact discs. 
 
Experimental protocols 
Action potentials were stimulated at various rates (75-600 bpm) using 5 ms current pulses of 1.2 x 
threshold strength, after current clamping resting cells at -75 mV and keeping the holding current 
constant thereafter. Only those cells which required a holding current of <150 pA immediately after 
establishing the whole cell configuration were used, and this frequently could be reduced following 
stimulation with a train of depolarising pulses, as reported previously in human atrial cells [22]. In 
subsequent action potential recordings, there was no significant difference in the holding current 
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between the groups of patients with SR and AF, at -66±6 and -64±19 pA (n=12 and 11 patients), 
respectively. The stimulus threshold current amplitude was initially determined in each cell by 
stimulating repetitively with trains of 3 current pulses, the 1st and 2nd being of equal, suprathreshold 
amplitude, and the 3rd pulse increasing progressively (from zero, in steps of 50 pA) until it produced a 
regenerative action potential. The ERP was measured using a standard S1-S2 stimulation protocol, with 
an 8-pulse conditioning train delivered at various rates, and S1 and S2 pulses of equal magnitude. The 
S1-S2 interval was shortened in 10 ms steps, and the ERP was defined as the longest S1-S2 interval 
which failed to elicit an S2 action potential of amplitude >80% of the preceding S1 action potential. The 
voltage clamp technique was used to record the voltage-dependency of ICaL, ITO, the sustained outward 
current (IKSUS) and IK1, and the frequency-dependency of ICaL. The same electrode filling solution was 
used as for recording action potentials, permitting the recording and comparison of all ion currents and 
action potentials under constant ionic conditions, and often in the same cell. To minimise, as far as 
possible, contamination from K
+
 currents, ICaL and ITO were measured after subtraction of steady-state 
(end-pulse) currents. The input resistance (Ri) was measured in each cell from the slope of the linear 
part of the current (usually recorded at around -100 mV) recorded in response to a linear voltage ramp 
(from -120 mV to +50 mV in 7 s). ICaL voltage-dependent activation was measured from a holding 
potential of -40 mV, with 100 ms duration voltage pulses (0.33 Hz), increasing in amplitude from -30 
mV to +50 mV in steps of 10 mV. The rate-dependency of ICaL was measured with trains of 20 pulses 
(50 ms duration) from -40 mV to +10 mV, delivered at progressively increasing rates from 75 to 600 
bpm, with a 5 s rest between trains. ITO and IKSUS were stimulated from a holding potential of -60 mV, 
with 100 ms pulses (0.33 Hz), increasing from -50 mV to +60 mV in steps of 10 mV. To study IK1, 
steady-state currents were measured at the end of 500 ms duration pulses (0.33 Hz), increasing in 10 
mV steps from -120 mV, with a holding potential of -40 mV. When superfusing cells with drugs, ion 
currents, action potentials and/or the ERP were recorded 90 s after drug addition, and again at 90 s 
intervals after drug removal until the reversal of any drug effect was confirmed. 
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Data analysis and statistics 
Patients were grouped according to their cardiac rhythm at the time of surgery. Only those in SR, or in 
AF which had persisted for at least the previous 6 months, were included. Patient data were analysed 
using Access software (Microsoft), and voltage and current data, using WinWCP. ICaL and action 
potential data were included only if the post cell-access time was ≤10 min, to avoid distortion by 
current "run-down". Cells were included for APD or ERP analysis only if the control APD90 was ≤290 
ms, consistent with Type 3 human atrial cells [23]. All currents were normalised to the cell's capacity. 
Values (means+SEM) were compared using two-tailed paired or unpaired Student's t tests, as 
appropriate. P<0.05 was regarded as statistically significant. 
 
 
Results 
 
Fast rate-induced depolarisation and APD-shortening was attenuated in cells from patients with AF 
Figure 1 shows that at the physiological rate of 75 bpm (top traces), action potentials recorded from a 
single atrial cell isolated from a patient with chronic AF displayed a markedly different morphology to 
those recorded in a cell from a patient in SR. Repolarisation was more linear in form than in the cell 
from the SR patient, with a less pronounced phase 1 and a markedly shorter late repolarisation. When 
the stimulation rate was increased to 300 bpm (cycle length: 200 ms) in the cell from the patient in SR 
(Figure 1, left hand panel), the upstroke of the second and subsequent action potentials impinged on the 
final stages of repolarisation of the respective preceding action potentials. This prevented full recovery 
of the resting potential following each response, causing depolarisation of the maximum diastolic 
potential (MDP). This depolarising effect became more pronounced as the rate was increased further, 
was marked at the fastest rates encountered during AF (ie: up to 600 bpm) and was fully reversible 
upon returning to 75 bpm (bottom trace). Despite such depolarisation at the highest rates, regenerative 
responses occurred but with reduced action potential amplitude (63 mV). This was substantially higher 
than that of the electrotonic ("just subthreshold”) responses (17 mV) measured at the start of the 
experiment. The stepwise increase in rate was accompanied by a progressive reduction in steady-state 
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APD at late repolarisation, with, for example, a 39% shortening in APD90 upon increasing from 75 to 
300 bpm stimulation. By contrast, in the cell from the patient with chronic AF (Figure 1, right hand 
panel), increasing the stimulation rate to 300 bpm produced a negligible change in the MDP, since the 
final phase of repolarisation of the post-rest action potential was sufficiently abbreviated in this cell not 
to be encroached upon by the reduced basic cycle length at this rate. Furthermore, even at rates as high 
as 600 bpm, such as these cells might have encountered in-vivo, the degree of MDP depolarisation was 
smaller than that seen in the cell from the patient in SR. 
 Figure 2 shows mean action potential data which confirmed that, at the physiological rate of 75 
bpm, chronic AF was associated with a marked and significant abbreviation in late (APD90), but not in 
early (APD50) repolarisation (panel A). The APD50 exhibited a moderate variation between cells, 
particularly in those from patients in SR, owing to the high sensitivity of this measurement to the height 
of the end of phase 1. The mean data also confirmed that increases in rate to 300 bpm and higher in 
cells from patients in SR produced both substantial shortening in late repolarisation, and depolarisation 
of the MDP (panel B). By contrast, in the cells from the patients with chronic AF, whilst a small 
depolarisation of the MDP and shortening in APD90 were evident at supraphysiological rates (Figure 2), 
the rate adaptation in these measurements was clearly markedly attenuated in comparison with that seen 
in the cells from the patients in SR.  
 
Atrial cell ERP was shortened and its rate adaptation attenuated in myocytes from AF patients 
The human atrial cell ERP was measured initially at the physiological basic rate of 75 bpm, as shown in 
the upper trace of Figure 3A, by the superimposed action potentials recorded in a single cell obtained 
from a patient in SR. A four-fold increase in the stimulation rate in this cell produced a marked 
reduction in the ERP, from 200 to 140 ms, as shown in the trace beneath. This effect was fully 
reversible upon returning to 75 bpm stimulation. By contrast, in a single cell obtained from a patient 
with chronic AF, the ERP was dramatically abbreviated at the physiological rate. Moreover, an increase 
in the rate to 300 bpm produced only a small degree of further ERP-shortening, of 20 ms (Figure 3A, 
lower trace pair). The high time resolution of these ERP recordings permitted accurate measurement of 
the maximum upstroke velocity, Vmax, which decreased from 203±11 to 159±20 V/s, when increasing 
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from 75 to 300 bpm (P<0.05, n=9 patients). A similar rate dependent reduction in Vmax occurred in the 
cells from the patients with AF (from 231±16 to 180±8 V/s; P<0.05, n=5 patients). Moreover, there was 
no significant difference in Vmax at the physiological rate, between the two patient groups. Figure 3B 
shows mean data on the ERP, obtained from each patient group. This confirmed that the ERP at 
physiological rates was markedly and significantly shorter in single atrial cells isolated from patients 
with chronic AF, than in those from patients in SR, by 49%. Additionally, this data confirmed a 
substantial adaptation of the ERP to a four-fold increase in rate in cells from patients in SR, with a 
significant and reversible shortening of mean ERP, by 27% (Figure 3B, left hand histogram). In cells 
from patients with chronic AF, by contrast (Figure 3B, right hand histogram), there was attenuation of 
the adaptation of the ERP to an increase in rate, with no significant shortening at higher rate. 
 
ICaL was reduced at physiological rates in atrial cells from patients with AF 
The current traces in Figure 4A show that the amplitude of ICaL was substantially reduced in a cell 
isolated from a patient with chronic AF, compared with that recorded in a cell from a patient in SR. 
Mean ICaL density-voltage relationship data in each patient group confirmed that chronic AF was 
associated with a marked and significant reduction in the density of ICaL at all potentials between -10 
and +30 mV, with a maximum reduction in peak ICaL of 63% (Figure 4A). This reduction in ICaL 
occurred without any alteration of its voltage-dependency, since the mean current-voltage relationship 
from each patient group superimposed when ICaL was expressed as a function of the maximum peak 
value obtained in each cell. The amplitude of peak ICaL was also measured at physiological rates and 
faster. Figure 4B (top trace) shows currents evoked by a train of voltage pulses delivered at 75 bpm in a 
cell from a patient in SR. There was an immediate and progressive reduction in peak ICaL following 
initiation of stimulation in this cell. Steady-state was reached by the eighth pulse, with an amplitude of 
only 58% of the post-rest value. This change in the Ca
2+
 current included a potentially interfering 
influence from outward currents, but this was minimised by the subtraction of end-pulse currents from 
peak ICaL. The trace beneath shows that a four-fold increase in rate, in the same cell, produced a rapid 
and substantial reduction in steady-state ICaL. In a cell from a patient with AF (Figure 4B, lower trace 
pair), both the post-rest and steady-state ICaL amplitudes were markedly smaller at 75 bpm, than in the 
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cell from the patient in SR. However, the effect of rate increase was similar in both cell types, with a 
diminution of ICaL at supraphysiological rates. Figure 4C shows mean data, including rates of up to 600 
bpm, which confirmed these changes and indicated that the contribution of the reduction in ICaL 
associated with chronic AF would be smaller at physiological rates and higher, than at sub 
physiological rate. 
 
ITO was reduced, IKSUS was unaltered and IK1 was increased in atrial cells from patients in AF 
Figure 5A shows that the rapidly activating, transient outward currents evoked by voltage pulses to 
between +10 and +60 mV, which represent ITO, were markedly reduced in amplitude in a cell isolated 
from a patient with chronic AF, compared with those recorded in a cell from a patient in SR. In 
contrast, the steady-state (end-pulse) currents, IKSUS, were similar in both cells. The mean IKSUS and ITO 
density-voltage relationships were calculated, from the end pulse currents and by subtraction of these 
from the transient peaks at each voltage step, respectively. These confirmed that chronic AF was 
associated with a marked and significant reduction in ITO, by 65% (Figure 5A, upper graph), but with no 
significant alteration in IKSUS (Figure 5A, lower graph). The reduction in ITO included no alteration in its 
voltage-dependency, since mean current density-voltage plots in cells from patients in SR and AF, 
respectively, superimposed when ITO was normalised to the peak value in each cell. The original traces 
in Figure 5B show that the amplitude of time-independent inward currents elicited at substantially 
hyperpolarised potentials (to more negative than approximately -100 mV), was larger in a cell isolated 
from a patient with AF, than in one from a patient in SR. Mean current density-voltage data confirmed 
this (Figure 5B, left hand panel), with a significantly larger inward current at -120 mV in the cells from  
patients with chronic AF (by 91%), but with no significant alteration at more positive potentials. The 
reversal potential of the steady-state currents was around -30 mV, as reported previously [12], and 
consistent with the low resting potential typically observed in these cells. Nevertheless, the slope of the 
current-voltage relationship between -120 and -100 mV indicated that it was largely representative of 
IK1. This indicated, therefore, that chronic AF was associated with an increase in the density of IK1. 
Quasi-steady-state current-voltage relationship data obtained to determine each cell's input resistance 
supported this, since the current measured at -115 mV was significantly larger in cells from patients 
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with AF, at -6.3±0.9 pA/pF (n=11 patients) compared with -3.6±0.2 pA/pF in cells from patients in SR 
(P<0.05; n=39 patients).  
 
Effects of independent and combined pharmacological inhibition of ICaL and ITO on APD and ERP  
Nifedipine (10 µmol/L) virtually abolished ICaL, with a reduction in the peak from -10.5±3.1 to -0.2±0.2 
pA/pF (P<0.05, n=4). Figure 6A shows the corresponding effects on action potentials and the ERP at 
physiological rate, in an atrial cell isolated from a patient in SR. Nifedipine had no effect on early 
repolarisation, but produced a small reduction in the plateau (left hand panel of Figure 6A) 
accompanied by a shortening in APD75 and APD90, but with little effect, however, on final 
repolarisation. The right hand panel of Figure 6A shows that in the same cell, the ERP was hardly 
affected by nifedipine, with a shortening of 10 ms. Table 2 shows mean data which confirmed that, in 
cells from patients in SR, ICaL inhibition, which had no effect on the MDP or APD50, produced a small 
but statistically significant reduction in both APD75 and APD90 (by 29 and 17%, respectively), but with 
no accompanying effect on the ERP. Superfusion of cells from patients in SR with 4-AP (2 mmol/L) 
reduced peak ITO from 12.7±3.4 to 5.9±1.0 pA/pF (P<0.05, n=4), and IKSUS from 7.0±1.3 to 3.3±0.6 
pA/pF (P<0.05, n=4). The left hand panel of Figure 6B shows that 4-AP suppressed phase 1 and 
substantially prolonged subsequent repolarisation. The right hand panel of Figure 6B shows that 4-AP 
also produced a marked lengthening in the ERP in a single cell, by 60 ms. Mean data confirmed these 
drug effects, with a marked and significant prolongation of all levels of repolarisation, and of the ERP 
by 33% (Table 2). Figure 6C illustrates the actions of the combination of 10 µmol/L nifedipine and 2 
mmol/L 4-AP in an atrial cell from a patient in SR. The left hand panel shows that whilst phase 1 was 
suppressed, in contrast with the effects of 4-AP on its own, subsequent repolarisation was not 
prolonged. Indeed, there was a slight shortening effect on late repolarisation in this cell. However, the 
ERP, recorded in the same cell (Figure 6C, right hand panel) was unaffected by this drug combination. 
Mean data (Table 2) confirmed that there was a negligible and statistically insignificant effect on either 
late repolarisation or the ERP, despite substantial prolongation in APD50 (by 177%), in the presence of 
combined pharmacological inhibition of ICaL and ITO. 
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Discussion 
 
 The ERP was measured, for the first time to our knowledge in human atrial isolated myocytes, and 
both its value at physiological rate and its adaptation to an increase in rate were in close agreement with 
those recorded in the right atrium of patients, including the appendage [8,9,24,25]. Moreover, in line 
with clinical studies [8,10], we demonstrated that chronic AF was associated with shortening of the 
ERP and APD, and attenuation in their adaptation to the high rates frequently encountered during AF. 
The magnitude of ERP reduction at physiological rate was substantial, and larger than in some studies 
in which the ERP was measured in patients after cardioversion of AF [8]. However, the reduction in late 
repolarisation was similar to that reported in human atrial cells [12].  
 Rates up to 600 bpm caused marked adaptation of both the MDP and APD in cells from patients in 
SR. Rate dependent APD shortening, and its attenuation by AF, has been reported at up to 240 bpm in 
human atrial cells [11,12]. Rate-dependent depolarisation of the MDP was reported in atrial trabeculae 
from dogs [26] and humans [23,27] at up to 270 bpm, but in human atrial cells, neither higher rates, 
effects of rate on the MDP, nor associated effects of AF, were reported [11,12]. Our data suggest that in 
unremodelled atrial cells exposed to sufficiently high rate, as might occur during paroxysmal AF, 
depolarisation of the MDP may result. This is consistent with the hypothesis that fast rate-induced 
depolarisation acts as a trigger of electrical remodelling in human atria, by contributing to intracellular 
Ca
2+
 overload [4]. Moreover, in cells from patients with chronic AF, abbreviation of late repolarisation, 
by permitting full recovery of the resting potential, largely attenuated such depolarisation, even at the 
highest rates encountered during AF [16]. In the canine model, AF also attenuated depolarisation [26]. 
These results support the notion that remodelling may be a cellular adaptive response to keep the APD 
short, and thus oppose Ca
2+
 overload, but at the expense of reentry-promoting ERP-shortening. 
 We demonstrated a marked rate-dependent reduction in ICaL, consistent with a contribution to the 
APD rate response. Chronic AF was associated with a substantial reduction (by 60-65%) in the fully 
reactivated ICaL and ITO, with no alteration in their voltage-dependency. The peak density of these 
currents in cells from patients in SR, and the magnitude of their reduction associated with AF, agreed 
with previous studies [2,11]. However, at physiological rate, ICaL was partially inactivated, due to its 
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slow reactivation kinetics [28], suggestive of a relatively reduced contribution of ICaL reduction to AF-
induced APD- and ERP-shortening. AF was also associated with an increased density of inwardly 
rectifying current at hyperpolarised potentials, representative of IK1. Consistent with this, an increase in 
human right atrial IK1 was associated with AF in one study [12], but an increase in IK1 in left, but not 
right, atrial cells has also been reported [15], and there was an absence of change in IK1 in canine atria 
[2]. The lack of a substantial change in IK1 over physiological potentials in the present study suggested 
only a limited involvement of this current in the shortening of APD and ERP. Human atrial IK includes 
the rapidly and slowly activating currents, IKr and IKs, respectively [29], and the ultra-rapidly activating, 
IKur [30], the main component of IKSUS [31]. IKSUS was similar in magnitude to that reported previously 
[12] and was not different between cells from patients in SR and AF. This is consistent with reports of a 
lack of change in both human atrial IKSUS [12] and IKur [13], as well as in canine atrial IKur [2], but is in 
conflict with other reports of a reduction in human atrial IKur or IKSUS [15,32]. We found that Vmax, 
measured at physiological rate, was similar in cells from patients with and without chronic AF, 
consistent with a lack of alteration in the Na
+
 current density reported in human atrium [12]. 
 In cells from patients without AF, nifedipine significantly shortened the action potential, 
particularly at around 75% repolarisation. This indicated an important contribution of ICaL to the APD 
and its rate adaptation [2,11,28] suggestive of an involvement of the reduction in ICaL associated with 
AF to the accompanying abbreviation in APD. However, the effect of nifedipine on the APD was 
relatively modest, as reported previously at physiological [2,28], in contrast with sub-physiological [2], 
rates, and particularly at final repolarisation. Moreover, the ERP, mainly determined by final 
repolarisation, was hardly affected by nifedipine, in contrast with the substantial shortening associated 
with AF. These data suggest that an exclusive reduction in ICaL would be insufficient to explain AF-
induced remodelling of action potentials and the ERP in human atrial myocytes. Inhibition of ITO using 
4-AP produced, by contrast, marked prolongation of both the single cell ERP and all levels of 
repolarisation. 4-AP shortened late repolarisation in canine atrial cells [2], presumably by prolonging 
the plateau and consequently enhancing voltage-dependent K
+
 currents [33], but this was also only 
reported at low rate (6 bpm) [2]. Moreover, the combination of nifedipine and 4-AP, despite prolonging 
early repolarisation at physiological rate, had no significant effect on either late repolarisation or the 
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ERP. Thus, the simultaneous reduction in atrial ICaL and ITO associated with human AF may not be 
sufficient to fully account for the marked shortening in late repolarisation and ERP which results from 
this arrhythmia. In support, a recent mathematical model [34] suggested that AF-induced remodelling of 
canine atrial ICaL and ITO cannot wholly explain associated changes in action potential morphology. 
Atrial electrophysiological remodelling by chronic AF, therefore, probably involves changes in 
additional ion channel, and/or exchanger or pump currents. 
 Potential limitations: 1) Studies on human cells involve inherently uncontrolled differences in 
patient drug regime, gender and disease state. Several cardiac diseases, often associated with AF, 
display distinct patterns of remodelling, eg: down regulation of atrial ITO in hypertrophy and heart 
failure [33], and of ICaL, ITO, IKs and IKr in myocardial infarction [35]. The majority of patients with AF 
underwent mitral valve surgery, alone or with other surgical procedures, whilst most patients in SR 
underwent coronary revascularisation only. Mitral valve disease is usually accompanied by atrial 
dilation, which may involve down regulation of ITO and ICaL [36]. Nevertheless, the dilation is most 
severe in the left atrium [37], and we studied only right atrial cells. 2) The chunk method of cell 
isolation may potentially disrupt ionic currents, eg: IK in canine atria [38]. 3) The majority of action 
potentials studied were of Type 3 [23], ie: with a plateau of relatively low amplitude. However, "spike 
and dome" (Type 1) action potentials [23,27], and those with extremely prolonged repolarisation [23] 
have also been reported, and these could have differing ERP and MDP rate responses, potentially 
contributing to electrical heterogeneity. Additionally, the ERP was recorded in the absence of the 
electrotonic influences and structural and electrophysiological heterogeneity which are present in-vivo. 
4) The results with 4-AP must be interpreted with caution, since whilst this is the best currently 
available ITO blocker, it is not entirely selective [39], blocking IKur at low concentration [40], and 
without effect on the Ca
2+
-dependent component of ITO [19]. Whilst IKur blockade could potentially 
prolong APD, a recent mathematical model [41] suggested, however, that inhibition of IKur by 50% (ie: 
similarly to that produced by 4-AP), would lengthen late repolarisation by only a small degree. 5) Of 
the patients who were in pre-operative SR, 29% developed AF post-operatively within the first week, 
and the possibility that cells from patients in SR included those with a pre-operative propensity for post-
operative AF cannot be excluded. 
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 In conclusion, chronic AF in humans is associated with shortening, and attenuation in rate 
adaptation, of the ERP in single atrial cells. The accompanying abbreviation in late repolarisation may 
largely prevent excessive depolarisation at high rates. Associated alterations in ICaL and ITO are probably 
insufficient to fully account for such changes. Our data may have important implications in the potential 
therapeutic modulation of AF-induced electrophysiological remodelling. 
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Table and Figure legends 
 
Table 1. Patients' clinical characteristics. 
Values are total numbers of patients in SR or chronic AF with selected clinical characteristics (n and % 
of total within rhythm group, respectively), except where parameter mean±SEM is shown. 
CABG=coronary artery bypass graft, AVR=aortic valve replacement, MVR=mitral valve replacement, 
ASD=atrial septal defect, VSD=ventricular septal defect, CCB=Calcium channel blocker, 
ACE=angiotensin converting enzyme, LVF=left ventricular function. 
 
Table 2. Effects of ICaL and ITO blockade on action potentials and ERP in atrial cells from patients in SR. 
Nif=nifedipine (10 µmol/L), 4-AP=4-aminopyridine (2 mmol/L). Stimulation rate=75 bpm in all cells. 
MDP=maximum diastolic potential (mV); APDx=action potential duration at x% repolarisation (ms); 
ERP=effective refractory period (ms).Values are means±SEM (n cells). Control data pooled from all 
drug experiments, but for statistical analyses, intervention data compared only with appropriate 
corresponding controls (ie: in same cells); *=P<0.05 vs corresponding control group (paired t-test). 
 
Figure 1. Effect of rate increase on action potentials and MDP in cells from patients with or without AF. 
Action potentials from a single atrial cell isolated from a patient in SR (left side) and from a single atrial 
cell from a patient with chronic AF (right), produced by stimulus trains of progressively increasing rate 
(labelled), with a 10 s pause between each train, before returning to 75 bpm stimulation. Dotted line=0 
mV. 
 
Figure 2. Rate-dependency of mean action potential parameters in cells from patients in SR and AF. 
A, Action potential duration (APD) at 50 and 90% repolarisation (labelled). B, Maximum diastolic 
potential (MDP). =SR (n=5 patients, 6 cells), =AF (5 patients, 7 cells). Values, measured from the 
15th action potential of a stimulus train, are mean±SEM; *=P<0.05 vs corresponding SR value at same 
rate, †=P<0.05 vs corresponding 75 bpm value of same action potential parameter. Recovery of changes 
upon rate decrease is shown following axis break (//). 
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Figure 3. Effect on the ERP of increasing rate in atrial cells from patients with and without AF. 
A, Superimposed action potentials recorded in response to the 7th and 8th of a train of 8 conditioning 
pulses of rates shown, followed by the responses to increasingly premature (in steps of -10 ms) test 
pulses in a single cell from a patient in SR, and in a single cell from a patient with chronic AF. Solid 
bars=ERP. B, Changes in mean (±SEM) ERP on increasing rate from 75 bpm (open columns labelled 
"C": Control) to 300 bpm (filled columns) and returning to 75 bpm (open column labelled "R": 
Recovery) in single cells from patients in SR or AF (n=8-13 cells, 6-9 patients and 4-7 cells, 2-5 
patients/rate, respectively). *=P<0.05 vs control rate, within rhythm; †=P<0.05 between control rates. 
 
Figure 4. Changes in atrial L-type Ca
2+
 current associated with rate increase and/or chronic AF. 
 and =data from patients in SR and AF, respectively; *=P<0.05 vs corresponding SR value. A, 
Mean (±SEM) steady-state peak ICaL density-voltage relationship, with representative traces in right 
hand panel (n=24 cells, 12 patients in SR and 18 cells, 7 patients with AF). Holding potential: -40 mV; 
voltage steps: 100 ms duration, 0.33 Hz. B, ICaL recorded in response to trains of voltage pulses (to +10 
mV, 50 ms duration) of rate shown, with each response number labelled above. //=break in trace. C, 
Rate-dependency of mean (±SEM) peak ICaL (n=7 cells, 6 patients in SR and 4 cells, 3 patients with 
AF). Rec=recovery. Post-rest value=response to first pulse of stimulus train, following a 5 s rest. 
Subsequent measurements taken from 15th response of each train. 
 
Figure 5. Changes in human atrial K
+
 currents associated with chronic AF. 
 and =data from patients with SR and AF, respectively; *=P<0.05 vs corresponding SR value. A, 
Mean (±SEM) current density-voltage relationship for ITO (upper left panel) and IKSUS (lower left panel); 
n=18 cells, 11 patients in SR and 9 cells, 5 patients with AF). Representative currents shown in right 
hand panel. Holding potential: -60 mV; voltage steps: 100 ms duration, 0.33 Hz. B, Mean (±SEM) IK1 
density-voltage relationship (n=8 cells, 6 patients in SR and 7 cells, 5 patients with AF). Holding 
potential: -40 mV; voltage steps: 500 ms duration, 0.33 Hz. Right hand panel shows representative 
currents recorded at 20 mV steps.  
 
CVRA/2001/0314/R1 
21 
Figure 6. Effects of nifedipine and 4-aminopyridine on action potentials and the ERP. 
Action potentials recorded in single atrial cells isolated from patients in SR in the absence (Control) and 
presence (after 90 s superfusion) of (A) nifedipine at 10 µmol/L (Nif), (B) 4-aminopyridine at 2 
mmol/L (4-AP) or (C) their combination. Left hand panels show superimposed action potentials 
recorded at steady-state (7th response of 75 bpm train) to illustrate drug effects. Right hand panels show 
superimposed action potentials evoked by the 7th and 8th of trains of 8 conditioning current pulses 
(rate: 75 bpm) followed by responses to increasingly premature test pulses, in the absence (upper traces) 
and presence (lower traces) of drugs. Solid bars=ERP. 
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Table 1 
 
 SR AF 
 n % n % 
Patients 
Male/female 
39 
31/8 
 
79/21 
11 
3/8 
 
27/73 
Age 59±2  65±2  
     
CABG 30 77 1 9 
AVR 4 10 0 0 
MVR 0 0 5 45 
AVR+MVR 0 0 2 18 
CABG+AVR 2 5 0 0 
CABG+MVR 0 0 3 27 
ASD repair 2 5 0 0 
VSD repair 1 3 0 0 
     
CCB 18 46 2 18 
ß-blocker 25 64 1 9 
Digoxin 2 5 10 91 
ACE inhibitor 14 36 3 27 
Nitrate 25 64 1 9 
Diuretic 9 23 10 91 
Lipid lowering 27 69 2 18 
Aspirin 24 62 2 18 
Warfarin 
 
LVF: 
Normal 
Mild/moderate 
Severe dysfunction 
2 
 
 
18 
17 
4 
5 
 
 
46 
44 
10 
10 
 
 
8 
2 
0 
91 
 
 
73 
18 
0 
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Table 2 
 
 
 
 
 
 
 
 
 
 Control Nif 4-AP Nif+4-AP 
MDP -79±1 (24) -79±1 (16) -76±2 (6)* -77±2 (8) 
APD50 22±4 (24) 20±3 (16) 76±15 (6)* 43±6 (8)* 
APD75 118±9 (24) 83±7 (16)* 176±18 (6)* 108±11 (8) 
APD90 203±10 (24) 170±10 (16)* 262±24 (6)* 186±16 (8) 
ERP 221±10 (18) 225±11 (11) 282±19 (5)* 210±4 (4) 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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